Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500123 · ClinicalTrials.gov registry record
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
A clinical trial of Alpha-1 Antitrypsin Deficiency, sponsored by University of Florida.
- Recruiting
- Registry status
- 50,000
- Enrollment target
- 1
- Study location
NCT00500123: Recruiting study of Alpha-1 Antitrypsin Deficiency, sponsored by University of Florida.
NCT00500123 is a study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by University of Florida. The registered enrollment target is 50,000 participants, above the 258-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (19280% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500123, a study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- 50,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
Primary Outcome
Rotating questionnaires assess the clinical course and co-morbidities associated with different genotypes of alpha-1 antitrypsin deficiency.
Conditions Studied
Interventions
- PROCEDURE Alpha-1 Antitrypsin Genotype
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50,000 participants |
| Start Date | 2001-01 |
| Est. Completion | 2050-01 |
What NCT00500123 shows while recruiting
NCT00500123 is an observational study that tracks outcomes without assigning an intervention. Its 50,000 participants enrollment target places it among the larger protocols in the corpus, above the 258-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (19280% higher).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Alpha-1 Antitrypsin Genotype is the first listed.
NCT00500123 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00500123 about?
NCT00500123 is a clinical study titled "The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study". The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
What is the current status of trial NCT00500123?
This trial is currently recruiting. The enrollment target is 50,000 participants. The study started on 2001-01. Estimated completion is 2050-01.
What conditions does trial NCT00500123 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT00500123?
The interventions under investigation include: Alpha-1 Antitrypsin Genotype (PROCEDURE).
Who is sponsoring clinical trial NCT00500123?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00500123 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00500123's enrollment target sits among peer trials
50,000 1st of 24 higher than 24 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
- NCT05497518 · 50,000 participants
The KidneyCARE (Community Access to Research Equity) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia